AU2021374843A1 - Compounds and their use in treatment of tachykinin receptor mediated disorders - Google Patents

Compounds and their use in treatment of tachykinin receptor mediated disorders Download PDF

Info

Publication number
AU2021374843A1
AU2021374843A1 AU2021374843A AU2021374843A AU2021374843A1 AU 2021374843 A1 AU2021374843 A1 AU 2021374843A1 AU 2021374843 A AU2021374843 A AU 2021374843A AU 2021374843 A AU2021374843 A AU 2021374843A AU 2021374843 A1 AU2021374843 A1 AU 2021374843A1
Authority
AU
Australia
Prior art keywords
nk2r
group
agonist
amino acids
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021374843A
Other languages
English (en)
Other versions
AU2021374843A9 (en
Inventor
Magnus Bernt Fredrik Gustafsson
Jakob Bondo HANSEN
Wouter Frederik Johan HOGENDORF
Johnny Madsen
Olivia MULVAD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2021374843A1 publication Critical patent/AU2021374843A1/en
Assigned to NOVO NORDISK A/S reassignment NOVO NORDISK A/S Request for Assignment Assignors: EMBARK BIOTECH APS
Publication of AU2021374843A9 publication Critical patent/AU2021374843A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021374843A 2020-11-09 2021-11-09 Compounds and their use in treatment of tachykinin receptor mediated disorders Pending AU2021374843A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206509 2020-11-09
EP20206509.0 2020-11-09
PCT/EP2021/081057 WO2022096736A1 (en) 2020-11-09 2021-11-09 Compounds and their use in treatment of tachykinin receptor mediated disorders

Publications (2)

Publication Number Publication Date
AU2021374843A1 true AU2021374843A1 (en) 2023-06-08
AU2021374843A9 AU2021374843A9 (en) 2024-08-08

Family

ID=73198203

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021374843A Pending AU2021374843A1 (en) 2020-11-09 2021-11-09 Compounds and their use in treatment of tachykinin receptor mediated disorders

Country Status (13)

Country Link
US (1) US20230406883A1 (https=)
EP (1) EP4240749A1 (https=)
JP (1) JP2023551122A (https=)
KR (1) KR20230106616A (https=)
CN (1) CN116745310A (https=)
AU (1) AU2021374843A1 (https=)
CA (1) CA3197916A1 (https=)
CL (1) CL2023001325A1 (https=)
CO (1) CO2023007404A2 (https=)
IL (1) IL302745A (https=)
MX (1) MX2023005408A (https=)
PE (1) PE20231952A1 (https=)
WO (1) WO2022096736A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023118263A1 (en) * 2021-12-21 2023-06-29 Embark Biotech Aps Agonists for treatment of eating disorder
CN117384258B (zh) * 2023-10-12 2024-07-26 湖南中晟全肽生物科技股份有限公司 一种神经激肽受体2（nk2r）激动剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2427475T3 (pl) * 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
CN105722526B (zh) * 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
TWI694082B (zh) * 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
WO2019059963A1 (en) * 2017-09-21 2019-03-28 Dignify Therapeutics, Llc COMPOSITIONS FOR INDUCING MICTION AND DEFECATION
US11633459B2 (en) * 2018-05-04 2023-04-25 Novo Nordisk A/S GIP derivatives and uses thereof
MX2022004566A (es) * 2019-10-17 2022-07-21 Univ Copenhagen Agonista del receptor de taquiquinina 2 (tacr2).

Also Published As

Publication number Publication date
CO2023007404A2 (es) 2023-07-10
EP4240749A1 (en) 2023-09-13
WO2022096736A1 (en) 2022-05-12
MX2023005408A (es) 2023-07-25
KR20230106616A (ko) 2023-07-13
IL302745A (en) 2023-07-01
US20230406883A1 (en) 2023-12-21
AU2021374843A9 (en) 2024-08-08
JP2023551122A (ja) 2023-12-07
CN116745310A (zh) 2023-09-12
CA3197916A1 (en) 2022-05-12
PE20231952A1 (es) 2023-12-06
CL2023001325A1 (es) 2023-12-15

Similar Documents

Publication Publication Date Title
KR102444783B1 (ko) 인크레틴 유사체 및 그의 용도
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
US20230406883A1 (en) Compounds and their use in treatment of tachykinin receptor mediated disorders
US12410227B2 (en) Incretin analogs and uses thereof
JP3765831B2 (ja) 改善された環状ｃｒｆ作用薬
GROSSMAN Gastrin and its activities
Beltramo et al. Rational design of triazololipopeptides analogs of kisspeptin inducing a long-lasting increase of gonadotropins
JPH0689035B2 (ja) Ｇｒｆ類似体類
WO1996019499A9 (en) Improved cyclic crf antagonists
US11572399B2 (en) Long-acting GIP peptide analogues
WO2023207107A1 (zh) Glp-1/gcg受体共激动剂、包含其的药物组合物及其用途
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
JP2002502381A (ja) 環状ｃｒｆアンタゴニストペプチド
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
Laimou et al. Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties
Niida et al. Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives
WO2023207106A1 (zh) Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
EA049082B1 (ru) Соединения и их применение для лечения нарушений, опосредованных тахикининовым рецептором
Batra et al. Pneumadin: a new lung peptide which triggers antidiuresis
US20260125440A1 (en) Incretin analogs and uses thereof
Warner et al. Purification, characterization, and spasmogenic activity of neurotensin from the toad Bufo marinus

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOVO NORDISK A/S

Free format text: FORMER APPLICANT(S): EMBARK BIOTECH APS

SREP Specification republished